//19 Sep 2011
The deputy of Indonesian Coordinating People’s Welfare Ministry, Emil Agustiono, has said that the country is ready to produce H5N1 vaccine for humans.
“Airlangga University in Surabaya has prepared the master seed. This master seed then will be produced to be a vaccine by Bio Farma,” Agustiono informed.
Related to the master seed, Prof. CA Nidom of Avian Influenza Research Center of Airlangga University said that the research had been started in 2005 in cooperation with molecular biologists from Japan. He continued, around 170 variants of avian influenza virus have been found in Indonesia. All variants were then classified into three different types: infecting animal, infecting human and infecting both animal and human. “By following the WHO’s recommendations, finally we found the variant which fulfill the aspect of immunology and its compatibility with field virus as master seed for vaccine,” he said.
Showing posts with label vaccine. Show all posts
Showing posts with label vaccine. Show all posts
19 September 2011
14 August 2011
Pfizer AH: A single-dose vaccine to prevent PCV2 viraemia in pigs
//11 Aug 2011
Veterinarians and pork producers in the United States can now help prevent Porcine Circovirus type 2 (PCV2) viraemia with the convenience of a single dose using new Fostera PCV from Pfizer Animal Health.
"Nearly all pigs are exposed to PCV2 during their lifetime, so the goal is to create an environment with the least amount of virus present," says Darrell Neuberger, DVM, pork technical services veterinarian at Pfizer Animal Health. "A challenge study demonstrated a single dose of Fostera PCV vaccine reduced the amount of PCV2 in the blood up to 10,000 times compared to non-vaccinated pigs."
PCV2 viraemia can compromise herd health, performance and kg per pig at market.
"Maintaining a low to non-existent PCV2 viremia level can enable the immune system to help fight other diseases more effectively and allow animals to grow more successfully," explains Neuberger.
Fostera PCV also helped provide protection against PCV2 infection in lymphoid tissues, while helping reduce lymphoid depletion in pigs challenged with virulent PCV2.
Costly disease
Porcine circovirus and mycoplasmal pneumonia are two of the costliest diseases affecting pork producers. Helping provide protection before disease exposure is critical to the success of any vaccination programme, explains Neuberger.
Studies show that pigs are typically infected with Mycoplasma hyopneumoniae within the first three weeks of their life - through exposure from the dam during lactation or through exposure to older pigs. Vaccinating after this point can leave a gap in protection.
"RespiSure-ONE at processing and Fostera PCV at weaning help fill a gap in protection without compromising convenience," says Neuberger.
Both products are available on the US market only.
Related news item:
• Pfizer Animal Health
Veterinarians and pork producers in the United States can now help prevent Porcine Circovirus type 2 (PCV2) viraemia with the convenience of a single dose using new Fostera PCV from Pfizer Animal Health.
"Nearly all pigs are exposed to PCV2 during their lifetime, so the goal is to create an environment with the least amount of virus present," says Darrell Neuberger, DVM, pork technical services veterinarian at Pfizer Animal Health. "A challenge study demonstrated a single dose of Fostera PCV vaccine reduced the amount of PCV2 in the blood up to 10,000 times compared to non-vaccinated pigs."
PCV2 viraemia can compromise herd health, performance and kg per pig at market.
"Maintaining a low to non-existent PCV2 viremia level can enable the immune system to help fight other diseases more effectively and allow animals to grow more successfully," explains Neuberger.
Fostera PCV also helped provide protection against PCV2 infection in lymphoid tissues, while helping reduce lymphoid depletion in pigs challenged with virulent PCV2.
Costly disease
Porcine circovirus and mycoplasmal pneumonia are two of the costliest diseases affecting pork producers. Helping provide protection before disease exposure is critical to the success of any vaccination programme, explains Neuberger.
Studies show that pigs are typically infected with Mycoplasma hyopneumoniae within the first three weeks of their life - through exposure from the dam during lactation or through exposure to older pigs. Vaccinating after this point can leave a gap in protection.
"RespiSure-ONE at processing and Fostera PCV at weaning help fill a gap in protection without compromising convenience," says Neuberger.
Both products are available on the US market only.
Related news item:
• Pfizer Animal Health
31 July 2011
Merck’s new coccidiosis vaccine approved for US poultry market
//22 Jul 2011
Merck Animal Health has obtained regulatory approval from the US Department of Agriculture for Coccivac-D2 — a new-generation version of a coccidiosis vaccine to replace Coccivac-D.
“Coccivac-D2 builds on the field-proven performance and dependability of Coccivac-D, but its spectrum is even more in step with the Eimeria populations found in today’s broiler-breeder and layer operations,” said Charlie Broussard, DVM, director of US poultry technical services.
He explained that Coccivac-D2 has a more focused antigen profile of the six major species of chicken coccidia (E. tenella, E. mivati, E. acervulina, E. maxima, E. brunetti and E. necatrix.) “We eliminated E. hagani and E. praecox, two of the least important pathogenic Eimeria species of the chicken,” Broussard added.
As with all Coccivac vaccines, Coccivac-D2 provides a balanced, controlled dose of live Eimeria oocysts to stimulate the bird’s natural immunity against this costly and highly prevalent disease. Coccivac-D2 is currently available in 5,000-dose and 1,000-dose vials.
The development of Coccivac-D2 is the result of Merck Animal Health’s ongoing commitment to quality control. As part of this process, all master seeds used to produce the vaccinal oocysts in Coccivac-D2 were tested for purity, quality and re-qualified by USDA. This new product will also help streamline production and result in a more efficient manufacturing process for Merck Animal Health coccidiosis vaccines for poultry.
Source: Merck Animal Health
Merck Animal Health has obtained regulatory approval from the US Department of Agriculture for Coccivac-D2 — a new-generation version of a coccidiosis vaccine to replace Coccivac-D.
“Coccivac-D2 builds on the field-proven performance and dependability of Coccivac-D, but its spectrum is even more in step with the Eimeria populations found in today’s broiler-breeder and layer operations,” said Charlie Broussard, DVM, director of US poultry technical services.
He explained that Coccivac-D2 has a more focused antigen profile of the six major species of chicken coccidia (E. tenella, E. mivati, E. acervulina, E. maxima, E. brunetti and E. necatrix.) “We eliminated E. hagani and E. praecox, two of the least important pathogenic Eimeria species of the chicken,” Broussard added.
As with all Coccivac vaccines, Coccivac-D2 provides a balanced, controlled dose of live Eimeria oocysts to stimulate the bird’s natural immunity against this costly and highly prevalent disease. Coccivac-D2 is currently available in 5,000-dose and 1,000-dose vials.
The development of Coccivac-D2 is the result of Merck Animal Health’s ongoing commitment to quality control. As part of this process, all master seeds used to produce the vaccinal oocysts in Coccivac-D2 were tested for purity, quality and re-qualified by USDA. This new product will also help streamline production and result in a more efficient manufacturing process for Merck Animal Health coccidiosis vaccines for poultry.
Source: Merck Animal Health
24 July 2011
Merck Animal Health begins vaccine plant expansion
//21 Jul 2011
Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, has embarked on the expansion of a vaccine manufacturing unit at its Biosciences Center Boxmeer campus in the Netherlands.
The $18 million investment will result in a doubling of the capacity of its Tissue Culture Department, one of the departments where antigens for viral and parasitological vaccines are manufactured for international markets.
The new facility, which is scheduled to be fully operational by early 2013, has been designed to operate with optimal efficiency as well as to meet current and future requirements with respect to Good Manufacturing Practice (GMP) and Safety, Health and Environment (SHE).
It will also allow for the anticipated globally growing demand for veterinary vaccines. In addition, the increase of the manufacturing capacity that will be realised anticipates for large-scale emergency production of veterinary vaccines when extensive amounts are needed within a short time period such as during outbreaks of emerging diseases.
Source: Merck Animal Health
Merck Animal Health, formerly known as Intervet/Schering-Plough Animal Health, has embarked on the expansion of a vaccine manufacturing unit at its Biosciences Center Boxmeer campus in the Netherlands.
The $18 million investment will result in a doubling of the capacity of its Tissue Culture Department, one of the departments where antigens for viral and parasitological vaccines are manufactured for international markets.
The new facility, which is scheduled to be fully operational by early 2013, has been designed to operate with optimal efficiency as well as to meet current and future requirements with respect to Good Manufacturing Practice (GMP) and Safety, Health and Environment (SHE).
It will also allow for the anticipated globally growing demand for veterinary vaccines. In addition, the increase of the manufacturing capacity that will be realised anticipates for large-scale emergency production of veterinary vaccines when extensive amounts are needed within a short time period such as during outbreaks of emerging diseases.
Source: Merck Animal Health
13 May 2011
Intervet/SP launches new atrophic rhinitis vaccine for pigs
//12 May 2011
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
04 May 2011
Ceva opens new poultry vaccine production facility
//04 May 2011
Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.
“After many years of building a strong research and development base, along with a fine sales force and excellent technical support, we are investing in our future growth with the opening of this new production facility,” said Dr. Arnaud Bourgeois, Vice President and Global Director of Biology at Ceva Santé Animale. “Increased demand for Ceva vaccines, plus the ability to create and utilize new vaccine technology not available from competitors made this the perfect time to build our new facility.”
Ceva Santé Animale purchased Lenexa-based Biomune Company in 2005, creating Ceva Animal Health as its US subsidiary. The purchase secured a strong foundation in research with Vectormune vaccines along with an aging manufacturing plant. With the opening of its new $18M facility, Ceva is poised to fill a global market need with high-quality vaccines. “Today, what we output is almost entirely for the domestic market,” explains Bourgeois, “ The new facility will double our domestic output while also allowing for expansion globally.” The existing plant will be renovated as part of Ceva’s long-term investment plan and is designated for a stand-alone custom vaccine project.
Ceva is well-known for its dedication to providing animal health products and services that ultimately benefit humans. The Biomune Campus’s contribution to the “One Health” effort is clear: poultry vaccines keep the world’s food supply safe and sufficient to meet the needs of an ever-growing population. “We continue to invest in our people and our facilities in order to innovate and therefore ensure that our products and services have a direct impact in improving global health,” said Marc Prikazsky, Chief Executive Officer of Ceva Santé Animale.
Ceva's new facility features:
· 55,000 square feet of innovative technology and automated systems
· State-of-the-art operations to ensure vaccine quality and consistent, safe supply
· Future physical plant growth/expansion opportunities
· Capability to product both standard and vector vaccines
· Career opportunities for 80 new production, research and development staff by 2015
Related website: CEVA
Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.
“After many years of building a strong research and development base, along with a fine sales force and excellent technical support, we are investing in our future growth with the opening of this new production facility,” said Dr. Arnaud Bourgeois, Vice President and Global Director of Biology at Ceva Santé Animale. “Increased demand for Ceva vaccines, plus the ability to create and utilize new vaccine technology not available from competitors made this the perfect time to build our new facility.”
Ceva Santé Animale purchased Lenexa-based Biomune Company in 2005, creating Ceva Animal Health as its US subsidiary. The purchase secured a strong foundation in research with Vectormune vaccines along with an aging manufacturing plant. With the opening of its new $18M facility, Ceva is poised to fill a global market need with high-quality vaccines. “Today, what we output is almost entirely for the domestic market,” explains Bourgeois, “ The new facility will double our domestic output while also allowing for expansion globally.” The existing plant will be renovated as part of Ceva’s long-term investment plan and is designated for a stand-alone custom vaccine project.
Ceva is well-known for its dedication to providing animal health products and services that ultimately benefit humans. The Biomune Campus’s contribution to the “One Health” effort is clear: poultry vaccines keep the world’s food supply safe and sufficient to meet the needs of an ever-growing population. “We continue to invest in our people and our facilities in order to innovate and therefore ensure that our products and services have a direct impact in improving global health,” said Marc Prikazsky, Chief Executive Officer of Ceva Santé Animale.
Ceva's new facility features:
· 55,000 square feet of innovative technology and automated systems
· State-of-the-art operations to ensure vaccine quality and consistent, safe supply
· Future physical plant growth/expansion opportunities
· Capability to product both standard and vector vaccines
· Career opportunities for 80 new production, research and development staff by 2015
Related website: CEVA
28 April 2011
Merial launches offer for Circovac PCV2 vaccine
//22 Apr 2011
Merial Animal Health has launched a cashback offer on its CircovacPCV2 vaccine. The offer represents a £10 discount for every 25 sow dose or 100 piglet dose pack of Circovac purchased by producers from their vet up to the end of July 2011.
Lynda Maris, Circovac brand manager said: “We know that these are tough times for everyone in the industry, and that every little helps. As Circovacis now licensed for piglets as well as sows, along with the cashback this means we can offer profitable PCV2 protection across the whole herd.”
Producers can obtain their cashback voucher when they purchase Circovacfrom their vet. All they need to do is complete the voucher and return it together with proof of purchase to the freepost address provided and they will be directly sent a cheque for their cashback!
PCV2 (Porcine Circovirus Type 2) is widely acknowledged as being one of the greatest problems affecting the pig industry in recent years. Indeed it is estimated to cost up to £468 million per annum across Europe. Furthermore, studies have demonstrated a marked Return on Investment ratio for vaccinating against PCV2 of at least 2.1:1 for piglet vaccination and 4.4:1 for sow vaccination1.
Circovacwas one of the first vaccines to market, and has been successfully used in sows since 2007. In January of 2011 it received a license for use in piglets as well. Ricardo Neto, Merial’s Veterinary Advisor, said: “Studies have shown that using Circovac to vaccinate sows remains the most cost-effective way of protecting the herd against PCV2. However, we recognise that there are circumstances in which piglet, or piglet and sow, vaccination is appropriate. Circovacnow offers the only ‘whole herd’ solution to PCV2, allowing producers and vets to vaccinate piglets, gilts and sows.”
For more information about using Circovac producers should speak to their veterinary surgeon.
Related website: Merial
Merial Animal Health has launched a cashback offer on its CircovacPCV2 vaccine. The offer represents a £10 discount for every 25 sow dose or 100 piglet dose pack of Circovac purchased by producers from their vet up to the end of July 2011.
Lynda Maris, Circovac brand manager said: “We know that these are tough times for everyone in the industry, and that every little helps. As Circovacis now licensed for piglets as well as sows, along with the cashback this means we can offer profitable PCV2 protection across the whole herd.”
Producers can obtain their cashback voucher when they purchase Circovacfrom their vet. All they need to do is complete the voucher and return it together with proof of purchase to the freepost address provided and they will be directly sent a cheque for their cashback!
PCV2 (Porcine Circovirus Type 2) is widely acknowledged as being one of the greatest problems affecting the pig industry in recent years. Indeed it is estimated to cost up to £468 million per annum across Europe. Furthermore, studies have demonstrated a marked Return on Investment ratio for vaccinating against PCV2 of at least 2.1:1 for piglet vaccination and 4.4:1 for sow vaccination1.
Circovacwas one of the first vaccines to market, and has been successfully used in sows since 2007. In January of 2011 it received a license for use in piglets as well. Ricardo Neto, Merial’s Veterinary Advisor, said: “Studies have shown that using Circovac to vaccinate sows remains the most cost-effective way of protecting the herd against PCV2. However, we recognise that there are circumstances in which piglet, or piglet and sow, vaccination is appropriate. Circovacnow offers the only ‘whole herd’ solution to PCV2, allowing producers and vets to vaccinate piglets, gilts and sows.”
For more information about using Circovac producers should speak to their veterinary surgeon.
Related website: Merial
21 March 2011
Foot-and-mouth disease vaccination 'viable' alternative to mass culling
//18 Mar 2011
Vaccinating livestock against Foot-and-Mouth disease (FMD) and returning them to the food chain could be a ‘viable alternative’ to mass culls in the case of a future outbreak.
This was said at a recent UK conference that hosted farmers, veterinarians food processors and the Scottish and UK governments. The meeting discussed the ‘significant’ role vaccinating animals could play in controlling a future epidemic - ten years on from the worst outbreak of the disease in the country.
Future control models for the disease may include vaccination of animals and then enter the food chain. Members of the meeting also discussed the practicalities of vaccine manufacture and distribution, when and how the vaccine could be used and challenges vaccination may present.
Veterinary virologist Peter Nettleton said vaccination was the ‘modern alternative’ to mass slaughter. He said: "The use of vaccination to resolve the next outbreak could help to prevent the tragic scenes, social upheaval and psychological trauma that were witnessed 10 years ago."
Nigel Miller, the President of NFU Scotland, said: "Fundamentally, we must find a way to avoid the scenes of mass slaughter of 2001. "The economic disruption caused by culling livestock from huge areas, and the scars that left on both individuals who were directly affected and the wider countryside, is not something any of us want to see again.
[Source: The Press Association]
Vaccinating livestock against Foot-and-Mouth disease (FMD) and returning them to the food chain could be a ‘viable alternative’ to mass culls in the case of a future outbreak.
This was said at a recent UK conference that hosted farmers, veterinarians food processors and the Scottish and UK governments. The meeting discussed the ‘significant’ role vaccinating animals could play in controlling a future epidemic - ten years on from the worst outbreak of the disease in the country.
Future control models for the disease may include vaccination of animals and then enter the food chain. Members of the meeting also discussed the practicalities of vaccine manufacture and distribution, when and how the vaccine could be used and challenges vaccination may present.
Veterinary virologist Peter Nettleton said vaccination was the ‘modern alternative’ to mass slaughter. He said: "The use of vaccination to resolve the next outbreak could help to prevent the tragic scenes, social upheaval and psychological trauma that were witnessed 10 years ago."
Nigel Miller, the President of NFU Scotland, said: "Fundamentally, we must find a way to avoid the scenes of mass slaughter of 2001. "The economic disruption caused by culling livestock from huge areas, and the scars that left on both individuals who were directly affected and the wider countryside, is not something any of us want to see again.
[Source: The Press Association]
Subscribe to:
Posts (Atom)